Dubai Healthcare City expands longevity offering

Dubai Healthcare City has expanded its longevity and pharmaceutical services at the World Health Expo Dubai 2026.

The expansion brings together what the free zone describes as a new longevity-led preventive care programme and an AI-driven tele-compounding pharmacy platform.

The additions expand the range of personalised care pathways available within the ecosystem, with a focus on long-term wellbeing, clinical governance and precision medicine.

Rashed Ahmed Alawadhi, director of property management at Dubai Healthcare City Authority, said: “Our role is to ensure that the physical and operational environment supports the next generation of healthcare delivery.

“The expansion of longevity-focused services alongside advanced pharmaceutical models such as AI-driven tele-compounding reflects how our infrastructure is evolving to meet the needs of specialised, precision-led care.

“By providing fit-for-purpose facilities and integrated developments, we enable healthcare providers to operate efficiently, scale responsibly, and deliver high-quality outcomes within the DHCC ecosystem.”

Proto Clinic is strengthening Dubai Healthcare City’s preventive care offering through the introduction of what it describes as a personalised, science-led programme within the ecosystem.

Designed to enhance healthspan, the period of life spent in good health, the programme integrates advanced diagnostics, genomics, lifestyle medicine and continuous monitoring to deliver individualised pathways.

Wissam Adada, founder and chairman of Proto Clinic, said: “Longevity medicine requires a shift from reactive treatment to a clinically grounded, preventive approach tailored to each individual.

“At Proto Clinic, we combine advanced diagnostics, genomics and lifestyle medicine to deliver personalised longevity pathways that improve healthspan and long-term wellbeing, guided by a decade of clinical practice and multidisciplinary expertise.

“Operating within DHCC’s ecosystem allows us to deliver the programme within a regulated, innovation-ready environment that supports high standards of clinical care.”

Dubai Healthcare City has also introduced The Formula, which it describes as the Middle East’s first AI-driven tele-compounding pharmacy platform, developed to enhance access to precision therapies. Compounding refers to the preparation of customised medicines for individual patients.

The Formula brings together clinical intelligence, pharmaceutical-grade compounding and AI decision-support in a single digital workflow.

Patients can access custom-compounded medications with personalised dosages, delivered through an end-to-end pathway that includes digital consultation, AI-augmented clinical assessment, bespoke formulation and regulated fulfilment.

The platform supports clinicians through decision-support tools, ensuring medical judgement remains central while enabling personalised therapies to be delivered.

Ameera Youssef, chief executive of Acorn Research and co-founder of The Formula, commented: “The launch of ‘The Formula’ within DHCC marks a significant milestone for personalised pharmaceutical care in the region.

“By combining AI-supported clinical insight with regulated compounding pharmacy workflows, we are redefining how customised medicines are prescribed, prepared and monitored, while ensuring patient safety and clinical governance remain central.”

Dubai Healthcare City was established in 2002 and is governed by Dubai Healthcare City Authority, a Dubai Government entity.